US Stock MarketDetailed Quotes
TTOO T2 Biosystems
- 0.8759
- -0.0741-7.80%
Close Oct 31 16:00 ET
- 0.8896
- +0.0137+1.56%
Post 19:52 ET
15.31MMarket Cap0.03P/E (TTM)
0.9535High0.8700Low455.86KVolume0.9300Open0.9500Pre Close407.46KTurnover8.90%Turnover RatioLossP/E (Static)17.48MShares8.379952wk High-2.60P/B4.49MFloat Cap0.870052wk Low--Dividend TTM5.12MShs Float122500.0000Historical High--Div YieldTTM8.79%Amplitude0.8700Historical Low0.8930Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
T2 Biosystems Stock Forum
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems (NASDAQ: TTOO) announced preliminary unaudited financial results for Q3 2024, reporting a 35% increase in total revenue compared to the prior year period. Key highlights include:
- Total revenue of $2.0 million
- Sepsis test panel revenue of $1.6 million, up 42% year-over-year
- Executed contracts for 11 T2Dx® Instruments
- Expanded international distribution to Malaysia and Indon...
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems (NASDAQ:TTOO) has successfully defended a key patent for its direct-from-whole blood detection method in the European Union. The opposition, filed in May 2023 by bioMerieux and an undisclosed party, challenged T2 Biosystems' European Patent No. 3 443 124. This patent is important to the company's intellectual property portfolio...
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
No comment yet